Aviragen Therapeutics, Inc.
News
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by SG Americas Securities LLC
Ticker Report SG Americas Securities LLC trimmed its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 50.1% during the second quarter, according to its most recent filing with the...\n more…
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Zacks Investment Research For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Atea Pharmaceuticals, Inc. (AVIR) been one of those stocks...\n more…
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway
Globe Newswire New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of...\n more…
California State Teachers Retirement System Cuts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Ticker Report California State Teachers Retirement System lowered its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 38.9% in the 1st quarter, according to its most recent Form 13F filing...\n more…
Price T Rowe Associates Inc. MD Has $272,000 Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
Zolmax Price T Rowe Associates Inc. MD grew its stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 21.7% in the 1st quarter, HoldingsChannel reports. The institutional investor owned...\n more…